News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Stock Titan Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Liminatus Pharma announced its common stock has been transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective August 4, 2026. The company also received an extension until September 3, 2026, to regain compliance with Nasdaq's minimum bid price requirement. Liminatus Pharma …
Liminatus Pharma (LIMN) shareholders approved a reverse stock split plan of up to 1-for-50 and other charter amendments during their 2026 Annual Meeting. This strategic move aims to help the company meet Nasdaq's minimum bid price and other listing requirements. Additionally, shareholders re-elected two …
This article provides an overview of Liminatus Pharma's (LIMN) recent SEC filings, highlighting that the company has submitted over 69 documents since 2024. It details key filing types like Form 4 for ownership changes, 8-K for material events, and 10-Q for quarterly financial updates. …
The article provides a revenue breakdown for Liminatus Pharma, Inc. (NASDAQ: LIMN) on TradingView. It indicates that the market was closed with no trades, and the content primarily consists of navigation and general information about TradingView's features rather than specific financial data for Liminatus …
Liminatus Pharma is awaiting a Nasdaq compliance decision regarding its stockholders' equity requirement after its merger with InnocsAI. The company claims its equity now surpasses the $2.5 million threshold needed to maintain its Nasdaq listing. Nasdaq will continue to monitor the company's equity level, …
Liminatus Pharma, Inc. (LIMN) announced that it believes its stockholders' equity now exceeds $2.5 million following its merger with InnocsAI LLC, awaiting Nasdaq's compliance determination. While the company hopes to meet the equity requirement, Nasdaq will continue monitoring its financial health, and future delisting …
Liminatus Pharma (LIMN) is facing delisting from Nasdaq due to failing to meet the minimum bid price requirement. The company was notified in January 2026 and, after a hearing in June, was informed in July 2026 that it still had not regained compliance and …
This article provides a revenue breakdown for Liminatus Pharma, Inc. (LIMN) listed on the Blue Ocean Alternative Trade System (BOATS). It directs users to financial data, statements, statistics, dividends, earnings, and segment performance available on TradingView, noting that the market is closed for this …
Liminatus Pharma received a delisting notification from Nasdaq for failing to meet the $1 minimum bid price requirement. The company is not eligible for a second compliance extension, and its fate will be decided by the Nasdaq Hearings Panel, which awaits a written response …
Samda Biolab Co., Ltd. has reported beneficial ownership of 5.1% of Liminatus Pharma, Inc. (LIMN) Common Stock, totaling 3,426,548 shares. This ownership gives Samda Biolab sole voting and dispositive power over these shares. The disclosure was made via a SCHEDULE 13G filing, indicating a …
This article provides a snapshot of Liminatus Pharma, Inc.'s growth, focusing on revenue, net income, and EPS growth rates. It highlights that revenue growth was nil in FY2025 and Q1 FY26. The company experienced significant negative net income and EPS growth rates in FY2025 …
This article provides financial information for Liminatus Pharma, Inc. (LIMNW) on TradingView, specifically focusing on its enterprise value to EBITDA forward. It indicates that no trades have occurred and the market is closed for this stock. The page is primarily a financial data listing, …
The article mentions the "Price to earnings forward" for Liminatus Pharma, Inc. (BOATS:LIMNW) and indicates that the market is currently closed with no trades. It appears to be a financial data snippet from a trading platform, potentially TradingView, listing basic company and market information.
This article identifies 12 health care stocks that experienced significant price movements during Thursday's intraday trading session. It highlights both gainers, such as Liminatus Pharma and Agape ATP, and decliners, including Alpha Compute and Senti Biosciences, detailing their stock performance, current prices, and market …
Search by ticker symbol or company name and select a result to open its chart.